Annals Internal Medicine, Author Interviews, COVID -19 Coronavirus / 18.04.2020
COVID-19 Resource Tool Estimates Maximum Numbers of Cases That Can Be Managed Daily
MedicalResearch.com Interview with:
[caption id="attachment_53949" align="alignleft" width="125"]
Dr. Nathan Stall[/caption]
Nathan Stall, MD, FRCPC
Geriatrics and Internal Medicine (Clinical Associate)
Sinai Health System and the University Health Network Hospitals
PhD Candidate, Clinical Epidemiology & Health Care Research
Institute of Health Policy, Management and Evaluation
Eliot Phillipson Clinician-Scientist Training Program
[caption id="attachment_53951" align="alignleft" width="125"]
Vasily Giannakeas[/caption]
Vasily Giannakeas, MPH
Epidemiologist/ Dedicated ICES Analyst
Women's College Hospital
Toronto, Ontario, Canada
MedicalResearch.com: What is the background for this study?
Response: As some health care systems approach collapse, a pressing need exists for tools modeling the capacity of acute and critical care systems during the COVID-19 pandemic.
We developed an online tool to estimate the maximum number of COVID-19 cases that could be managed per day within the catchment area served by a health care system, given acute and critical care resource availability.
The COVID-19 Acute and Intensive Care Resource Tool (CAIC-RT) is open access and available at https://caic-rt.shinyapps.io/CAIC-RT.
Dr. Nathan Stall[/caption]
Nathan Stall, MD, FRCPC
Geriatrics and Internal Medicine (Clinical Associate)
Sinai Health System and the University Health Network Hospitals
PhD Candidate, Clinical Epidemiology & Health Care Research
Institute of Health Policy, Management and Evaluation
Eliot Phillipson Clinician-Scientist Training Program
[caption id="attachment_53951" align="alignleft" width="125"]
Vasily Giannakeas[/caption]
Vasily Giannakeas, MPH
Epidemiologist/ Dedicated ICES Analyst
Women's College Hospital
Toronto, Ontario, Canada
MedicalResearch.com: What is the background for this study?
Response: As some health care systems approach collapse, a pressing need exists for tools modeling the capacity of acute and critical care systems during the COVID-19 pandemic.
We developed an online tool to estimate the maximum number of COVID-19 cases that could be managed per day within the catchment area served by a health care system, given acute and critical care resource availability.
The COVID-19 Acute and Intensive Care Resource Tool (CAIC-RT) is open access and available at https://caic-rt.shinyapps.io/CAIC-RT.


Aurika Savickaite[/caption]
Aurika Savickaite RN
Adult Gerontology Acute Care Nurse Practitioner
Bulletproof Coach
University of Chicago Medicine
MedicalResearch.com: Would you briefly explain what is meant by helmet-based ventilation? How does it work?
Response: For patients in respiratory failure, noninvasive positive pressure ventilation (NIPPV) is usually delivered through a nasal mask or facemask. Many patients develop pain, discomfort – even claustrophobia -- from using NIPPV systems. The transparent helmet was developed to improve the tolerance of noninvasive ventilation. It allows the patient to see, read, speak and drink without interrupting noninvasive positive-pressure ventilation (NPPV).
The helmet has a sealed connection and a soft collar that adheres to the neck which helps prevent the air leaks that are very common with nasal- or face masks. High positive end-expiratory pressure (PEEP) is vital in treating patients in respiratory failure and thanks to helmets “none to minimum air leak” system, PEEP can be set high (up to 25). NIPPV via a nasal- or full-face mask typically begins to show air leaks when the required pressure exceeds 15-20cm H2O.


Dr. Bin Cao[/caption]
Bin Cao, Yeming Wang, Guohui Fan,
Lianghan Shang, Jiuyang Xu, DingyuZhang, Chen Wang
on behalf of LOTUS-China Study Group
China-Japan Friendship Hospital; Wuhan Jintinyan Hospital;
Institute of Respiratory Medicine, Chinese Academy of Medical Science
MedicalResearch.com: What is the background for this study?
Response: In the past two months, the outbreak of Coronavirus Disease 2019 (COVID-19) has been spreading rapidly across the world. Science and technology is the most powerful weapon for human to fight against diseases, especially in such a pandemic setting. Seeking for effective antiviral medication is the most critical and urgent among the many scientific tasks in the pandemic.
At the most critical moment in the fight against COVID-19, Chinese clinical scientists have stepped forward under extremely difficult research conditions to carry out clinical trials in antiviral treatment including lopinavir–ritonavir and remdesivir, in a swift, decisive and effective manner. These trials have attracted worldwide attention.
Recently, the Lopinavir–ritonavir Trial for suppression of SARS-CoV-2 in China (LOTUS-China) has been completed, which, with great clinical significance, can provide strong evidence for the treatment of COVID-19 both in China and around the world.
